HB 1407 would create a new section of Florida law governing compounding pharmacies and the use of compounded medications for certain seriously ill patients. The bill defines “chronically ill patient,” “terminally ill patient,” “compounding pharmacy,” and “monographs,” and states that chronically ill and terminally ill patients may work with their health care providers to determine individualized treatment courses using medications and treatments obtained from compounding pharmacies.
The bill also authorizes Florida-licensed compounding pharmacies to obtain active pharmaceutical ingredients that do not have a USP, National Formulary, or Food Chemicals Codex monograph, so long as the ingredients come from FDA-registered manufacturers, repackagers, relabelers, or wholesalers and are shipped into the state with a certificate of analysis showing quality specifications. It excludes ingredients withdrawn by the FDA for safety or efficacy reasons and limits use of substances on the interim 503A category II or III bulk drug substances lists to those meeting the bill’s requirements. The bill expressly states that it does not authorize any treatment intended to cause the patient’s death.
If enacted, HB 1407 would expand the statutory framework for compounding pharmacies in Florida by creating s. 465.191, F.S., and by clarifying when compounded medications may be used for chronically ill and terminally ill patients. It would also set conditions under which Florida compounding pharmacies may source certain active pharmaceutical ingredients that lack standard monographs, potentially broadening access to customized medications while imposing sourcing, documentation, and federal-compliance safeguards. The bill would take effect July 1, 2025.
The available record shows limited formal debate or recorded votes, so overall sentiment cannot be measured in detail. The bill’s structure suggests a generally supportive intent toward expanding access to individualized compounded treatments for seriously ill patients while maintaining safety guardrails. Its failure to advance, however, indicates that it did not secure enough support in the Health Professions & Programs Subcommittee.
The main points of contention likely center on patient access versus drug-safety oversight. Supporters would emphasize giving chronically ill and terminally ill patients and their providers more flexibility to obtain individualized therapies from compounding pharmacies, especially when commercially available options are lacking. Opponents or cautious lawmakers may have been concerned about allowing use of ingredients without standard monographs, the reliability of sourcing from nontraditional supply chains, and whether the bill could create loopholes around FDA oversight or compound medications that approach unapproved drug manufacturing. The bill attempts to address these concerns by excluding FDA-withdrawn substances and prohibiting any use intended to cause death.